{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+Lymphomas&page=29", "query": { "condition": "Relapsed Lymphomas", "page": 29 }, "page_size": 10 }, "pagination": { "page": 29, "page_size": 10, "total_count": 2067, "total_pages": 207, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+Lymphomas&page=30&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+Lymphomas&page=28&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T20:24:44.751Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01030536", "title": "Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "CAT-8015 20 mcg/kg", "type": "DRUG" }, { "name": "CAT-8015 30 mcg/kg", "type": "DRUG" }, { "name": "CAT-8015 40 mcg/kg", "type": "DRUG" }, { "name": "CAT-8015 50 mcg/kg", "type": "DRUG" }, { "name": "CAT-8015 60 mcg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 23, "start_date": "2010-02-15", "completion_date": "2013-03-04", "has_results": true, "last_update_posted_date": "2018-04-09", "last_synced_at": "2026-11-14T20:24:44.751Z", "location_count": 7, "location_summary": "Los Angeles, California • Indianapolis, Indiana • Bethesda, Maryland + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01030536" }, { "nct_id": "NCT01980628", "title": "Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Marginal Zone Lymphoma", "B-cell Lymphoma" ], "interventions": [ { "name": "ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2013-12", "completion_date": "2017-10-02", "has_results": true, "last_update_posted_date": "2019-10-16", "last_synced_at": "2026-11-14T20:24:44.751Z", "location_count": 13, "location_summary": "Tucson, Arizona • Duarte, California • Santa Monica, California + 8 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01980628" }, { "nct_id": "NCT00426764", "title": "A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral T-cell Lymphoma" ], "interventions": [ { "name": "Romidepsin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 131, "start_date": "2007-06-19", "completion_date": "2018-05-17", "has_results": true, "last_update_posted_date": "2020-02-11", "last_synced_at": "2026-11-14T20:24:44.751Z", "location_count": 45, "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 35 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00426764" }, { "nct_id": "NCT06026319", "title": "CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-hodgkin Lymphoma", "Relapsed Non-Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Follicular Lymphoma", "Marginal Zone Lymphoma", "Diffuse Large B Cell Lymphoma", "Primary Mediastinal Large B-cell Lymphoma (PMBCL)", "High-grade B-cell Lymphoma", "Grade 3b Follicular Lymphoma", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "CD79b-19 CAR T cells", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marcela V. Maus, M.D.,Ph.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2023-10-26", "completion_date": "2028-08-01", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-11-14T20:24:44.751Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06026319" }, { "nct_id": "NCT00014664", "title": "Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "apolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "PDL BioPharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-11-14T20:24:44.751Z", "location_count": 1, "location_summary": "Freemont, California", "locations": [ { "city": "Freemont", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00014664" }, { "nct_id": "NCT00671112", "title": "Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "714leukemia", "Lymphoma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brian Hill, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2008-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-10-28", "last_synced_at": "2026-11-14T20:24:44.751Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00671112" }, { "nct_id": "NCT00054665", "title": "PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-Cell Lymphoma" ], "interventions": [ { "name": "PS-341", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2003-02", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2012-09-11", "last_synced_at": "2026-11-14T20:24:44.751Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Buffalo, New York", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00054665" }, { "nct_id": "NCT00309907", "title": "Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Chronic Myelogenous Leukemia", "Childhood Myelodysplastic Syndromes", "Chronic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Disseminated Neuroblastoma", "Juvenile Myelomonocytic Leukemia", "Previously Treated Childhood Rhabdomyosarcoma", "Previously Treated Myelodysplastic Syndromes", "Pulmonary Complications", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Neuroblastoma", "Recurrent Wilms Tumor and Other Childhood Kidney Tumors", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes" ], "interventions": [ { "name": "etanercept", "type": "BIOLOGICAL" }, { "name": "methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 39, "start_date": "2006-04", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2017-09-29", "last_synced_at": "2026-11-14T20:24:44.751Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Arcadia, California • Loma Linda, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Arcadia", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00309907" }, { "nct_id": "NCT05011058", "title": "An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Epstein-Barr Virus Associated Lymphoma", "EBV-Positive DLBCL, NOS", "EBV-Related Non-Hodgkin Lymphoma", "EBV Related PTCL, NOS", "EBV-Related Hodgkin Lymphoma", "EBV-Related PTLD", "EBV-Related Lymphoproliferative Disorder" ], "interventions": [ { "name": "Nanatinostat in combination with valganciclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Viracta Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2021-05-28", "completion_date": "2025-01-31", "has_results": true, "last_update_posted_date": "2025-07-28", "last_synced_at": "2026-11-14T20:24:44.751Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Duarte, California • Los Angeles, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05011058" }, { "nct_id": "NCT01534715", "title": "IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "IMGN529", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunoGen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2012-01", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2017-12-29", "last_synced_at": "2026-11-14T20:24:44.751Z", "location_count": 6, "location_summary": "Boston, Massachusetts • New York, New York • Columbus, Ohio + 3 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01534715" } ] }